Our study suggests that Sema3E could be considered as a novel treatment for chronic allergic asthma via regulation of both Th2, e.g. IL-4 and IL-5, and Th17, e.g. IL-17A, associated cytokines. This evidence concerns the gene IL17A and allergic asthma.